Current Controversies: Are Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D Status than Total Levels?

Endocrinology and Metabolism Clinics of North America

Volumn 46, Issue 4, 2017, Pages 901-918

  Bikle, Daniel D ^a   Malmstroem, Sofie ^b,c   Schwartz, Janice ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Free hormone hypothesis; Free vitamin D; Liver disease; Pregnancy; Vitamin D; Vitamin D metabolism

Indexed keywords

25 HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CHOLESTANETRIOL 26 MONOOXYGENASE; COLECALCIFEROL 24 HYDROXYLASE; CUBILIN; MEGALIN; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE; VITAMIN D; VITAMIN D BINDING PROTEIN; 1,25-DIHYDROXYVITAMIN D; 25-HYDROXYVITAMIN D;

ALCOHOL LIVER DISEASE; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN THERAPY; HAPLOTYPE; HUMAN; HYDROXYLATION; HYPOTHYROIDISM; IMMUNOASSAY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER CIRRHOSIS; MULTIPLE CHRONIC CONDITIONS; OBESITY; PREGNANT WOMAN; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRAFILTRATION; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; VITAMIN D DEFICIENCY;

HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85032457731     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2017.07.013     Document Type: Review

References (71)

1. Bikle, D.D., Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol Metab 21:6 (2010), 375–384.
2. Houghton, L.A., Vieth, R., The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 84:4 (2006), 694–697.
3. Hollis, B.W., Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites. J Steroid Biochem 21:1 (1984), 81–86.
4. Horst, R.L., Reinhardt, T.A., Ramberg, C.F., et al. 24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process. J Biol Chem 261:20 (1986), 9250–9256.
5. Zhu, J.G., Ochalek, J.T., Kaufmann, M., et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A 110:39 (2013), 15650–15655.
6. Moghadasian, M.H., Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 27:1 (2004), 42–50.
7. Cheng, J.B., Motola, D.L., Mangelsdorf, D.J., et al. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 278:39 (2003), 38084–38093.
8. Bianco, S.D., Peng, J.B., Takanaga, H., et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res 22:2 (2007), 274–285.
9. Cheng, J.B., Levine, M.A., Bell, N.H., et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 101:20 (2004), 7711–7715.
10. Bikle, D., Extra renal synthesis of 1,25-dihydroxyvitamin D and its health implications. Holick, M., (eds.) Vitamin D: physiology, molecular biology, and clinical applications, 2010, Humana Press, New York, 277–295.
11. Bikle, D.D., Pillai, S., Gee, E., et al. Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology 129:1 (1991), 33–38.
12. Bikle, D.D., Pillai, S., Gee, E., et al. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 124:2 (1989), 655–660.
13. St-Arnaud, R., Messerlian, S., Moir, J.M., et al. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 12:10 (1997), 1552–1559.
14. Jones, G., Prosser, D.E., Kaufmann, M., 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 523:1 (2012), 9–18.
15. Plachot, J.J., Du Bois, M.B., Halpern, S., et al. In vitro action of 1,25-dihydroxycholecalciferol and 24,25- dihydroxycholecalciferol on matrix organization and mineral distribution in rabbit growth plate. Metab Bone Dis Relat Res 4:2 (1982), 135–142.
16. Brozyna, A.A., Jochymski, C., Janjetovic, Z., et al. CYP24A1 expression inversely correlates with melanoma progression: clinic-pathological studies. Int J Mol Sci 15:10 (2014), 19000–19017.
17. Sakaki, T., Sawada, N., Komai, K., et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 267:20 (2000), 6158–6165.
18. Mendel, C.M., The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl 13:2 (1992), 107–116.
19. Recant, L., Riggs, D.S., Thyroid function in nephrosis. J Clin Invest 31:8 (1952), 789–797.
20. Refetoff S. Thyroid hormone serum transport proteins. In: De Groot LJ, Chrousos G, Dungan K, et al, editors. Endotext. South Dartmouth (MA); 2000.
21. Siiteri, P.K., Murai, J.T., Hammond, G.L., et al. The serum transport of steroid hormones. Recent Prog Horm Res 38 (1982), 457–510.
22. Bouillon, R., Van Assche, F.A., Van Baelen, H., et al. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest 67:3 (1981), 589–596.
23. Safadi, F.F., Thornton, P., Magiera, H., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 103:2 (1999), 239–251.
24. Arnaud, J., Constans, J., Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 92:2 (1993), 183–188.
25. Mendel, C.M., Rates of dissociation of sex steroid hormones from human sex hormone-binding globulin: a reassessment. J Steroid Biochem Mol Biol 37:2 (1990), 251–255.
26. Nykjaer, A., Dragun, D., Walther, D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:4 (1999), 507–515.
27. Nykjaer, A., Fyfe, J.C., Kozyraki, R., et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 98:24 (2001), 13895–13900.
28. Lundgren, S., Carling, T., Hjalm, G., et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 45:3 (1997), 383–392.
29. Bikle, D.D., Gee, E., Halloran, B., et al. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest 74:6 (1984), 1966–1971.
30. Bikle, D.D., Siiteri, P.K., Ryzen, E., et al. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 61:5 (1985), 969–975.
31. Bikle, D.D., Gee, E., Halloran, B., et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63:4 (1986), 954–959.
32. Bikle, D.D., Halloran, B.P., Gee, E., et al. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Invest 78:3 (1986), 748–752.
33. Bikle, D.D., Genant, H.K., Cann, C., et al. Bone disease in alcohol abuse. Ann Intern Med 103:1 (1985), 42–48.
34. Guarino, M., Loperto, I., Camera, S., et al. Osteoporosis across chronic liver disease. Osteoporos Int 27:6 (2016), 1967–1977.
35. Herlong, H.F., Recker, R.R., Maddrey, W.C., Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83:1 Pt 1 (1982), 103–108.
36. Matloff, D.S., Kaplan, M.M., Neer, R.M., et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83:1 Pt 1 (1982), 97–102.
37. Heaney, R.P., Skillman, T.G., Calcium metabolism in normal human pregnancy. J Clin Endocrinol Metab 33:4 (1971), 661–670.
38. Hammond, G.L., Nisker, J.A., Jones, L.A., et al. Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem 255:11 (1980), 5023–5026.
39. Schwartz, J.B., Lai, J., Lizaola, B., et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab 99:5 (2014), 1631–1637.
40. Bikle, D., Bouillon, R., Thadhani, R., et al. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?. J Steroid Biochem Mol Biol, 2017, 10.1016/j.jsbmb.2017.01.007.
41. Pettifor, J.M., Bikle, D.D., Cavaleros, M., et al. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med 122:7 (1995), 511–513.
42. Nielson, C.M., Jones, K.S., Bouillon, R., et al. Role of assay type in determining free 25-hydroxyvitamin D levels in diverse populations. N Engl J Med 374:17 (2016), 1695–1696.
43. Nielson, C.M., Jones, K.S., Chun, R.F., et al. Free 25-hydroxyvitamin D: impact of vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab 101:5 (2016), 2226–2234.
44. Song, Y.H., Naumova, A.K., Liebhaber, S.A., et al. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res 9:6 (1999), 581–587.
45. Yang, F., Brune, J.L., Naylor, S.L., et al. Human group-specific component (Gc) is a member of the albumin family. Proc Natl Acad Sci U S A 82:23 (1985), 7994–7998.
46. Bouillon, R., Van Baelen, H., Rombauts, W., et al. The purification and characterisation of the human-serum binding protein for the 25-hydroxycholecalciferol (transcalciferin). Identity with group-specific component. Eur J Biochem 66:2 (1976), 285–291.
47. Daiger, S.P., Schanfield, M.S., Cavalli-Sforza, L.L., Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci U S A 72:6 (1975), 2076–2080.
48. Malik, S., Fu, L., Juras, D.J., et al. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci 50:1 (2013), 1–22.
49. Sonderman, J.S., Munro, H.M., Blot, W.J., et al. Reproducibility of serum 25-hydroxyvitamin D and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 176:7 (2012), 615–621.
50. Bouillon, R., Xiang, D.Z., Convents, R., et al. Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein. J Steroid Biochem Mol Biol 42:8 (1992), 855–861.
51. Marikanty, R.K., Gupta, M.K., Cherukuvada, S.V., et al. Identification of urinary proteins potentially associated with diabetic kidney disease. Indian J Nephrol 26:6 (2016), 434–445.
52. Madden, K., Feldman, H.A., Chun, R.F., et al. Critically ill children have low vitamin D-binding protein, influencing bioavailability of vitamin D. Ann Am Thorac Soc 12:11 (2015), 1654–1661.
53. Dahl, B., Schiodt, F.V., Ott, P., et al. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med 31:1 (2003), 152–156.
54. Powe, C.E., Evans, M.K., Wenger, J., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369:21 (2013), 1991–2000.
55. Hoofnagle, A.N., Eckfeldt, J.H., Lutsey, P.L., Vitamin D-binding protein concentrations quantified by mass spectrometry. N Engl J Med 373:15 (2015), 1480–1482.
56. Farrell, C.J., Martin, S., McWhinney, B., et al. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem 58:3 (2012), 531–542.
57. Su, Z., Narla, S.N., Zhu, Y., 25-Hydroxyvitamin D: analysis and clinical application. Clin Chim Acta 433 (2014), 200–205.
58. Muller, M.J., Volmer, D.A., Mass spectrometric profiling of vitamin D metabolites beyond 25-hydroxyvitamin D. Clin Chem 61:8 (2015), 1033–1048.
59. Van Eeckhaut, A., Lanckmans, K., Sarre, S., et al. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 877:23 (2009), 2198–2207.
60. Shah, I., James, R., Barker, J., et al. Misleading measures in vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars. Nutr J, 10, 2011, 46.
61. Schwartz, J.B., Lai, J., Lizaola, B., et al. Variability in free 25(OH) vitamin D levels in clinical populations. J Steroid Biochem Mol Biol 144:Pt A (2014), 156–158.
62. Higashi, T., Shibayama, Y., Fuji, M., et al. Liquid chromatography-tandem mass spectrometric method for the determination of salivary 25-hydroxyvitamin D3: a noninvasive tool for the assessment of vitamin D status. Anal Bioanal Chem 391:1 (2008), 229–238.
63. Lee, M.J., Kearns, M.D., Smith, E.M., et al. Free 25-hydroxyvitamin D concentrations in cystic fibrosis. Am J Med Sci 350:5 (2015), 374–379.
64. Sollid, S.T., Hutchinson, M.Y., Berg, V., et al. Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D. Eur J Endocrinol 174:4 (2016), 445–452.
65. Alzaman, N.S., Dawson-Hughes, B., Nelson, J., et al. Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation. Am J Clin Nutr 104:1 (2016), 205–214.
66. Shieh, A., Chun, R.F., Ma, C., et al. Effects of high-dose vitamin D2 versus D3 on total and free 25-hydroxyvitamin D and markers of calcium balance. J Clin Endocrinol Metab 101:8 (2016), 3070–3078.
67. Aloia, J., Dhaliwal, R., Mikhail, M., et al. Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover. J Clin Endocrinol Metab 100:11 (2015), 4140–4145.
68. Schwartz, J.B., Kane, L., Bikle, D., Response of vitamin D concentration to vitamin D3 administration in older adults without sun exposure: a randomized double-blind trial. J Am Geriatr Soc 64:1 (2016), 65–72.
69. Aloia, J., Mikhail, M., Dhaliwal, R., et al. Free 25(OH)D and the vitamin D paradox in African Americans. J Clin Endocrinol Metab 100:9 (2015), 3356–3363.
70. Walsh, J.S., Evans, A.L., Bowles, S., et al. Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. Am J Clin Nutr 103:6 (2016), 1465–1471.
71. Kane, L., Moore, K., Lütjohann, D., et al. Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. J Clin Endocrinol Metab 98 (2013), 4400–4409.